Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gleevec Extends Post-Surgery GIST Survival Significantly; Wins Full Adjuvant Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Patients who took Novartis’ Gleevec for three years after surgery to remove gastrointestinal stromal tumors had a 54% reduction in risk of recurrence and a 55% reduction in risk of death compared to patients who took it for only one year.

You may also be interested in...



Novartis Glivec Make It Through NICE For GISTs With Expanded Label

After a prior rejection, Britain’s NICE has backed Novartis’ Glivec for KIT (CD117)-positive GISTS, even accepting an expanded-treatment duration of three years compared to the original single year.

FDA Cites Gleevec For Promoting Unapproved Indications Three Weeks Before Expanding Label

Notice of violation letter to Novartis from FDA’s Office of Prescription Drug Promotion expresses concern about describing a patient with five-year survival data, a claim that was added to the label the following month.

For Novartis, 2012 Is Set To Be A Bumpy Ride

With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel